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60 Poster Session-Inot in CR at SCT. Randomized studies are needed to determine
the role of RIC in MDS/AML pts in CR at SCT. The novel mod-
MAC regimens are relatively well tolerated even in pts not eligible
for MAC and may be more effective than standard RIC in refrac-
tory disease.159
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT) FOR PROLYM-
PHOCYTIC LEUKEMIA (PLL)
Kalaycio, M., Kukreja, M., Szer, J., Woolfrey, A., Cortes, J., Arora, M.
CIBMTR, Milwaukee, WI
Although PLL is indolent in some people, most affected persons
die within 1 year. Several case reports suggest a benefit to allogeneic
HCT.We sought to determine if this hypothesis is correct in the ob-
servational database of the Center for International Blood and Mar-
row Transplant Research.We retrospectively reviewed data from 47
subjects transplanted between1995 and 2006. Median age was 54 y
(range, 30–75 y). Karnofsky performance score was .80% in 30
(75%). Immunophenotype was B-cell in 11 (23%), T-cell in 21
(45%), and unknown in 15 (32%). Six patients (13%) had a splenec-
tomy and 16 (36%) were in complete remission (CR) at the time of
transplant. Donors were HLA-matched siblings or well-matched
unrelated donors in 34 (70%). Conditioning regimens included
high-doses of radiation or busulfan in 19 (40%), low-doses in 14
(30%), and neither in 14 (30%) includingmelphalan (N5 7) and flu-
darabine-containing regimens (N5 6). Grafts were blood cells in 31
(66%). Grade 2–4 acute graft versus host disease (GvHD) developed
in 52% (95% confidence interval (CI) 38–66%) of transplant recip-
ients. 1 year incidence of chronic GVHD was 42% (CI 28–57%).
Treatment related mortality (TRM) was 28% (CI 16–42%) and oc-
curred within 1 yr of transplant. Common causes of non-relapse
mortality were infection (N 5 4; 12%), GvHD (N 5 5; 15%), and
pneumonitis/ARDS (n 5 3;9%). PLL progression was the most
common cause of death (N 5 16; 49%). Median progression-free
survival (PFS) and overall survival (OS) is 5 and 11 mos, respectively.
Median PFS for 16 subjects transplanted in CR is 8.9 mo. Median
PFS for patients with matched siblings or well-matched donors
(N 5 34) is 5.2 mo. With a median follow-up of survivors of 13
mos, the 1y PFS and OS is 33% (CI 20–47%) and 48% (CI 33–
62%), respectively. At 2y, the PFS is also 33% (CI 20–47%) and
OS is 35% (CI 21–50%). These data provide information on antic-
ipated outcomes of allotransplants for PLL.160
PROLONGED SURVIVAL IN ADULTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL) FOLLOWING REDUCED INTENSITY CONDITIONING
WITH CORD BLOOD OR SIBLING DONOR TRANSPLANTATION
Bachanova, V., Verneris, M.R., Brunstein, C., Weisdorf, D. University of
Minnesota, Minneapolis,, MN
The optimal therapy for adult ALL patients.35 years or intoler-
ant of myeloablative allotransplantation is uncertain. Twenty-two
adult ALL patients received reduced intensity conditioning (RIC)
followed by allogeneic transplantation. All patients were high risk
with 64% having Ph1 ALL and 46% in $2nd remission, 20/22
were in cytogenetic CR. Following a uniform preparative regimen
(fludarabine 40 mg/m2/day  5, cyclophosphamide 50 mg/kg/day
and 200 cGy total body irradiation) patients received either umbilical
cord (UCB, n5 18) or matched related (MRD, n5 4) donor grafts.
All patients reached neutrophil engraftment (median 10 days) and
100% donor chimerism (median day 23). Overall survival, treatment
related mortality and relapse were 50% (95% confidence interval
[CI], 27–73%), 27% (95%CI, 9–45%), 36% (95%CI, 14–58%) at
3 years, respectively. There were no relapses beyond 2 years. OS,
TRM and relapse following cord blood HCT were 49% (95%CI,
23–75%), 28% (95%CI, 8–48%) and 33% (95%CI, 9–57%). The
cumulative incidence of acute (grade II-IV) and chronic graft versus
host disease was 55% and 45%.HCT inCR1 led to less TRM (8%vs
50%, p\0.04) and improved OS (81% vs 15%, p\0.01). For ALL
adults in CR1, RIC allografting using UCB or MRD results in
modest TRM, limited risk of relapse and promising leukemia-free
survival.161
ADOPTIVE T CELL THERAPY USING EDUCATED T CELLS GENERATED BY
THE SEQUENTIAL STIMULATION WITH DC/TUMOR FUSION CELLS AND
ANTI-CD3/CD28
Rosenblatt, J.1, Vasir, B.2, Wu, Z.2, Zarwan, C.1, Stone, R.2,
Bissonnette, A.2, Friedman, T.2, Stevenson, K.2, Neuberg, D.2,
Mills, H.1, Glotzbecker, B.1, Levine, J.D.1, Joyce, R.1, Boussiotis, V.1,
Tzachanis, D.1, Spentzos, D.1, Konstantinopoulos, P.1, Kufe, D.2,
Avigan, D.1 1Beth Israel Deaconess Medical Center, Boston, MA;
2Dana Farber Cancer Institute, Boston, MA
Acute leukemia is susceptible to T cell mediated killing as evi-
denced by the graft versus disease effect following allogeneic trans-
plantation. The development of adoptive immunotherapy to more
selectively target tumor cells is an area of interest. Ligation of the
CD3/CD28 complex results in expansion of T cells ex vivo with
a phenotype that is dependent on the immunologic milieu during
stimulation. We have developed a cancer vaccine in which autolo-
gous tumor cells are fused with dendritic cells (DCs). We postu-
lated that stimulation with fusions followed by anti-CD3/CD28
would result in the expansion of activated T cells targeting tumor
antigens. Tumor was obtained from peripheral blood or bone mar-
row of patients with AML. DCs were generated from adherent
mononuclear cells cultured with rhIL-4, GM-CSF and TNFand
fused with tumor cells by coculture in polyethylene glycol. T cells
were stimulated by fusions prior to or following exposure to
antiCD3/CD28 antibody coated plates. Stimulation by fusions fol-
lowed by anti-CD3/CD28 resulted in the synergistic expansion of
T cells, manifested by a greater stimulation index (SI) compared
to stimulation by either pathway alone (SI 8.2 versus 3.3 with fu-
sions alone). A rise in CD41/CD251 cells was noted following se-
quential stimulation with fusions and anti-CD3/CD28 (9.3% vs.
2.7% with fusions alone). An higher percentage of CD41/
CD251 cells expressed IFNg when exposed to fusions followed
by anti-CD3/CD28 (7% compared to 2% with fusions alone). As
compared to un-stimulated T cells, stimulation with fusions or
anti-CD3/CD28 resulted in a 3.3 and 3.8 fold increase in CD81
T cells expressing granzyme B, respectively. In contrast, sequential
stimulation with fusions and anti-CD3/CD28 induced a 19-fold ex-
pansion of granzyme B1 cells consistent with enhanced cytolytic
capacity. In spectratyping analysis, T cells undergoing sequential
stimulation with fusions and anti-CD3CD28 demonstrate greater
skewing of CDR3-size usage in the T cell receptor as compared
to T cells stimulated by fusions or anti-CD3/CD28 alone. The pat-
tern of gene expression in T cells stimulated sequentially by fusions
and anti-CD3CD28 is being assessed. In conclusion, sequential
stimulation of T cells by fusions and anti-CD3/CD28 results in
the expansion of tumor reactive activated T cells. A clinical trial
evaluating the use of T cells generated by sequential stimulation
with DC/tumor fusions and anti-CD3CD28 for patients with acute
leukemia is planned.162
IMPAIRED PRE-TRANSPLANT FEV1 IS ASSOCIATED WITH REDUCED
OVERALL AND DISEASE FREE SURVIVAL FOLLOWING ALLOGENEIC
TRANSPLANT FOR ACUTE MYELOGENOUS LEUKEMIA
Magenau, J.1, Maslak, J.2, Mineishi, S.1, Digiandamenico, S.2,
Braun, T.1, Levine, J.E.1, Yanik, G.A.1 1University of Michigan, Ann
Arbor, MI; 2University of Michigan, Ann Arbor, MI
Introduction: Pulmonary function testing (PFT) is routinely per-
formed prior to allogeneic hematopoetic stem cell transplant
(HSCT), but its relationship to survival is poorly described. In this
report, the post-transplant survival outcomes of Acute Myelogenous
Leukemia (AML) patients are examined with respect to pre-trans-
plant pulmonary function.
Methods: Two hundred fifty one patients with AML receiving
HSCT between January 2001 and May 2008 at the University of
Michigan were retrospectively analyzed for pre-transplant PFTs by
forced expiratory volume at one second (FEV1), forced vital capacity
(FVC), and diffusion capacity (DLCO). PFT function parameters
FEV1 ($80% vs. \80%), FVC ($80% vs. \80%), and DLCO
($65% vs. \65%) were correlated with overall (OS) and disease
free survival (DFS). Using a multivariate Cox regression analysis,
OS and DFS were modeled for the following risk factors: age at
